Once is not enough: clinical trials in sepsis.
Daniel A
DA
Sweeney
Robert L
RL
Danner
Peter Q
PQ
Eichacker
Charles
C
Natanson
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic / Q000941:ethics / Q000379:methods; D004345:Drug Industry / Q000941:ethics; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D015337:Multicenter Studies as Topic / Q000941:ethics / Q000379:methods; D010919:Placebos; D011486:Protein C / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000941:ethics / Q000379:methods; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000627:therapeutic use; D012107:Research Design; D012772:Shock, Septic / Q000188:drug therapy* / Q000401:mortality; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
D000305:Adrenal Cortex Hormones; D000890:Anti-Infective Agents; D000911:Antibodies, Monoclonal; D007328:Insulin; D010919:Placebos; D011486:Protein C; D017472:Receptors, Interleukin-1; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated